The report on Eli Lilly and Company was published on April 11, 2026. Share the report or generate your own report on Finsight Alpha.

Eli Lilly and Company logo

Eli Lilly and Company

Neutral/Bullish
Ticker: LLY · https://www.lilly.com

Executive Summary

Investors are grappling with the dual challenge of Eli Lilly and Company's declining market share in India's weight-loss drug sector and the increasing competition from generics. The company's market share fell from 61% to 56% in just one month, raising concerns about its ability to sustain growth in a market where competitors like Novo Nordisk are holding steady. While Eli Lilly's commitment to scaling production of its weight-loss pill and the recent uptick in institutional investment signal potential for recovery, the competitive pressures and pricing challenges present significant risks.

This mixed outlook complicates the investment landscape for Eli Lilly. The company has demonstrated strong revenue growth and cash generation, yet rising operational challenges, particularly in working capital management, could strain its financial health. Investors should closely monitor how Eli Lilly navigates these dynamics, especially in light of the high valuation metrics that suggest a premium on future growth. The coming months will be critical as the company seeks to balance innovation with the realities of a competitive market.

Next reported earnings: Thursday, 30 April 2026, before market open.

Eli Lilly and Company 6-Month Share Price

Key Metrics

Market Cap $887.63 B i
6-Month Share Price Change 12.72% i
Revenue (TTM) $65.18 B i
EBITDA (TTM) $27.94 B i
EPS (TTM) $22.98 i
Operating Cash Flow (TTM) $16.81 B i
Free Cash Flow (TTM) $8.97 B i
Cash and cash equivalents $7.16 B i
P/E Ratio (TTM) 40.88 i
Price/Book (TTM) 31.79 i
Debt/Equity 1.60 i
Current Ratio 1.58 i
Dividend Yield (TTM) 0.66% i

Tap or click the i icon for a metric definition.

The Eli Lilly and Company Story

Founded in 1876 and headquartered in Indianapolis, Eli Lilly and Company has established itself as a leader in the pharmaceutical industry. The company focuses on developing innovative medicines across various therapeutic areas, including diabetes, oncology, immunology, and neurodegeneration. Eli Lilly's commitment to research and development has led to significant breakthroughs, such as the introduction of insulin in the 1920s and the development of the first oral medication for diabetes in the 1990s.

In recent years, Eli Lilly has pivoted towards biotechnology, enhancing its portfolio with biologic therapies. The launch of Trulicity, a once-weekly injectable for type 2 diabetes, marked a major milestone, contributing to substantial revenue growth. Additionally, the company's acquisition of Loxo Oncology in 2019 expanded its capabilities in targeted cancer therapies, showcasing its strategic shift towards precision medicine.

However, the landscape remains competitive, with ongoing challenges from generic drug manufacturers and pricing pressures. Eli Lilly's focus on innovation and strategic partnerships positions it well to navigate these hurdles while continuing to deliver impactful therapies to patients worldwide.

Macro Industry Position

The US healthcare sector, particularly the Drug Manufacturers - General industry, operates within a complex framework shaped by payer and reimbursement pressures, regulatory risks, and rising employment costs. This environment influences how companies fund research and development initiatives. Eli Lilly and Company stands alongside notable peers such as Pfizer, Merck, and Bristol-Myers Squibb, each vying for market share in a competitive landscape marked by innovation and strategic acquisitions.

Eli Lilly distinguishes itself through its focus on innovative therapies, particularly in diabetes and oncology. The company's recent advancements, such as the launch of Trulicity, highlight its commitment to addressing significant health challenges. Competitors like Novo Nordisk and Amgen also push boundaries in drug development, yet Eli Lilly's strategic acquisitions, including Loxo Oncology, enhance its capabilities in targeted therapies, giving it a competitive edge in the evolving market.

Demand for healthcare products remains strong, driven by an aging population and increasing prevalence of chronic diseases. Consumers are prioritizing healthcare spending, despite rising prices. As inflation continues to affect budgets, the pressure on end-customers may influence purchasing decisions in the pharmaceutical sector. Companies like Eli Lilly must navigate these dynamics carefully to sustain growth and meet the evolving needs of patients and healthcare providers.

Rising inflation impacts household budgets, which in turn affects spending on healthcare products. With US inflation at 3.3 % year over year, consumers may tighten their wallets, influencing demand for Eli Lilly's offerings. The Fed-funds rate remains steady at 3.64 %, which maintains a challenging environment for financing research and development. Eli Lilly must navigate these economic pressures while ensuring it can fund its innovative pipeline. The US 10-year yield stands at 4.29 %, reflecting investor sentiment and the cost of capital for long-term projects, further complicating financial strategies in the pharmaceutical sector.

Bottom line: Eli Lilly and Company operates in a healthcare landscape shaped by payer pressures and demographic demand, while macroeconomic factors like inflation and interest rates pose challenges. The company's focus on innovative therapies positions it well, but it must remain agile to adapt to shifting consumer spending habits and financing costs. Balancing these dynamics will be crucial for sustaining growth and meeting the needs of patients and healthcare providers in a competitive market.

Recent Developments

Eli Lilly and Company (LLY) faced a decline in its market share in India's weight-loss drug sector, dropping to 56% in March from 61% in February 2026. This decrease occurred as generic versions of semaglutide entered the market, intensifying competition. In contrast, Novo Nordisk maintained its market share at 25% during the same period, indicating a stable position amidst the influx of cheaper alternatives.[1]

On April 7, 2026, Eli Lilly's CEO stated that the company was ready to scale production of its weight-loss pill. This announcement highlighted the company's commitment to meeting growing demand for its obesity treatment, which has gained significant attention in recent months. The CEO's remarks suggested confidence in the product's market potential and the company's operational capabilities.[2]

Additionally, on April 10, 2026, Apella Capital LLC disclosed that it had increased its holdings in Eli Lilly by 51.8% during the fourth quarter of 2025. The firm owned 3,174 shares after acquiring an additional 1,083 shares. This move indicated a growing interest from institutional investors in Eli Lilly's stock, reflecting confidence in the company's future performance.[3]

For investors, these updates suggest a mixed outlook for Eli Lilly. While the company is poised to increase production of its weight-loss pill, the decline in market share in India raises concerns about competitive pressures. The increased institutional investment may signal confidence in the company's long-term prospects, but investors should monitor the evolving competitive landscape closely.[2][3][1]

Sources

  • [1] Eli Lilly market share drops, Novo Nordisk holds firm as generic weight-loss drugs flood India (Apr 10, 2026)
  • [2] Eli Lilly (LLY) CEO Says Company Ready to Scale Production of Weight-Loss Pill - TipRanks (Apr 7, 2026)
  • [3] Apella Capital LLC Acquires 1,083 Shares of Eli Lilly and Company $LLY (Apr 10, 2026)

Financial Deep-Dive

Welcome to the Financial Deep-Dive. The eight tabs below organise Eli Lilly and Company's financial data into valuation, profitability, per-share data, leverage, liquidity, efficiency, working-capital, and R&D. Each tab presents financial metrics and trend charts for its category, along with key strengths and weaknesses. Click on any measure for a clear definition and insight into its relevance for investors. At the bottom, you'll find a detailed Financial Health Summary outlining Eli Lilly and Company's financial condition based on their most recent accounts.

Valuation and Market Multiples

  • Market capitalization: $887.63 B (status: green)
  • Price-to-earnings ratio: 40.88 (status: red)
  • Price-to-sales ratio: 13.62 (status: red)
  • Price-to-book ratio: 31.79 (status: red)
  • Enterprise-value/EBITDA multiple: 33.04 (status: red)
  • EV-to-operating-cash-flow: 54.90 (status: red)
  • EV-to-free-cash-flow: 102.87 (status: red)
  • Earnings yield: 2.45% (status: green)

Profitability Ratios

  • Net profit margin: increased over the period (status: green)
  • Return on equity (ROE): increased over the period (status: green)
  • Operating profit margin: increased over the period (status: green)
  • Gross profit margin: increased over the period (status: green)
  • Return on assets (ROA): increased over the period (status: green)
  • Return on capital employed (ROCE): increased over the period (status: green)
  • Pretax profit margin: increased over the period (status: green)
  • Return on invested capital (ROIC): increased over the period (status: green)
  • Income quality: decreased over the period (status: red)
  • Return on tangible assets: increased over the period (status: green)

Per-Share and Key Metrics

  • Earnings per share (EPS): $22.98 (status: green)
  • Revenue per share: increased over the period (status: green)
  • Operating cash flow per share: increased over the period (status: green)
  • Free cash flow per share: increased over the period (status: green)
  • Cash per share: $8.09 (status: red)
  • Book value per share: $29.55 (status: green)
  • Tangible book value per share: $15.72 (status: green)
  • Interest-bearing debt per share: $47.33 (status: red)
  • Payout ratio: 26.09% (status: green)
  • Dividend per share: $6.23 (status: green)
  • Dividend yield: 0.66% (status: green)

Leverage and Coverage Ratios

  • Debt-to-equity ratio: 1.60 (status: amber)
  • Debt ratio: 0.38 (status: green)
  • Interest coverage: 37.34 (status: green)
  • Total debt to capitalization: 0.62 (status: amber)
  • Long-term debt to capitalization: 0.61 (status: red)
  • Cash-flow-to-debt ratio: 0.40 (status: green)

Liquidity Ratios

  • Cash and cash equivalents: $7.16 B (status: green)
  • Current ratio: 1.58 (status: amber)
  • Quick ratio: 1.19 (status: amber)
  • Cash ratio: 0.20 (status: red)

Activity and Efficiency Ratios

  • Asset turnover: increased over the period (status: green)
  • Receivables turnover: decreased over the period (status: red)
  • Inventory turnover: decreased over the period (status: red)
  • Payables turnover: decreased over the period (status: red)
  • Fixed-asset turnover: decreased over the period (status: red)
  • Operating cash flow-to-sales ratio: decreased over the period (status: red)
  • Free cash flow-to-operating cash flow ratio: increased over the period (status: green)

Working-Capital and Cycle Metrics

  • Cash conversion cycle: decreased over the period (status: green)
  • Days of sales outstanding: decreased over the period (status: green)
  • Days of inventory outstanding: decreased over the period (status: green)
  • Days of payables outstanding: decreased over the period (status: red)
  • Operating cycle: decreased over the period (status: green)

Capital-Intensity and R&D

  • R&D expense-to-revenue ratio: decreased over the period (status: green)
  • Capital expenditure-to-revenue ratio: increased over the period (status: red)
  • Capex-to-operating-cash-flow ratio: increased over the period (status: red)
  • Capex per share: increased over the period (status: red)
  • Capex-to-depreciation ratio: increased over the period (status: red)
  • Stock-based compensation-to-revenue ratio: decreased over the period (status: green)

Financial Health Summary

Eli Lilly and Company reported significant growth in fiscal year 2025, achieving revenue of $65.18 billion and EBITDA of $27.94 billion, both substantial increases from $45.04 billion and $15.23 billion in fiscal year 2024. In the latest quarter, the company generated revenue of $19.29 billion and EBITDA of $8.39 billion, reflecting a strong performance. Operating cash flow for the trailing twelve months stood at $16.81 billion, indicating robust cash generation capabilities.

The company's market capitalization reached $887.63 billion, with a price-to-earnings ratio of 40.88 and a price-to-sales ratio of 13.62, suggesting that investors are willing to pay a premium for its earnings and sales. However, the price-to-book ratio of 31.79 and the enterprise-value-to-EBITDA multiple of 33.04 indicate a high valuation relative to its assets and earnings before interest, taxes, depreciation, and amortization. Eli Lilly's liquidity position is supported by $7.16 billion in cash and cash equivalents, although its current ratio of 1.58 and quick ratio of 1.19 suggest some caution regarding short-term obligations.

Despite the positive revenue and cash flow trends, Eli Lilly faces challenges in operational efficiency. The cash conversion cycle has increased, indicating that the company is tying up more days in working capital, which could strain liquidity. Additionally, days of inventory outstanding have risen, suggesting that inventory management may need attention. Days of payables outstanding have also increased, reflecting slower payments to suppliers, which can support cash flow but warrants monitoring to avoid potential supply chain issues.

Verdict: Eli Lilly and Company demonstrates strong revenue growth and cash generation, yet it must address rising working capital challenges to maintain operational efficiency. The high valuation metrics indicate investor confidence, but the increasing cash conversion cycle and inventory days could pose risks if not managed effectively.

Risks and Concerns

Eli Lilly's recent decline in market share in India's weight-loss drug sector, dropping from 61% to 56% in just one month, underscores significant operational risks. This shift coincides with the entry of generic versions of semaglutide, intensifying competition. As competitors like Novo Nordisk maintain a stable market share, Eli Lilly's ability to sustain growth in this segment is increasingly uncertain.

While Eli Lilly's commitment to scaling production of its weight-loss pill reflects a proactive approach, the broader market dynamics present challenges. The company faces pricing pressures and the threat of generics, which could erode its competitive edge. Moreover, with US inflation at 3.3% year over year, consumer spending on healthcare products may tighten, further complicating demand for Eli Lilly's offerings.

For shareholders, the implications of these operational and market risks are significant. Eli Lilly's high valuation metrics, including a price-to-earnings ratio of 40.88, suggest that investors are banking on continued growth. However, if the company cannot effectively navigate the competitive landscape and manage its rising working capital challenges, the premium investors are willing to pay could diminish, impacting overall shareholder value.

Outlook

Eli Lilly's recent challenges in India's weight-loss drug sector underscore a critical juncture for the company. The decline in market share, now at 56%, reflects intensified competition from generics, particularly as Novo Nordisk maintains a stable position. This shift raises questions about Eli Lilly's ability to sustain growth in a market increasingly flooded with cheaper alternatives. However, the company's commitment to scaling production of its weight-loss pill signals a proactive approach to meet rising demand, which could help mitigate some of these competitive pressures.

Institutional investment trends also provide a glimmer of optimism. The 51.8% increase in holdings by Apella Capital suggests growing confidence in Eli Lilly's long-term prospects. This backing could bolster the company's financial stability as it navigates the current landscape. Investors should closely monitor how Eli Lilly adapts its strategies in response to market dynamics, particularly in production capabilities and competitive positioning. The coming months will be crucial as the company seeks to balance innovation with the realities of a challenging market environment.

Red & Green Flags

This section distills all of the report's positives (green flags), negatives (red flags) and open questions (unknowns) into one place.

Green Flags

  • Eli Lilly's market capitalization reached $887.63 billion, indicating strong investor confidence.
  • The company achieved significant revenue growth, with fiscal year 2025 revenue at $65.18 billion, up from $45.04 billion in 2024.
  • Eli Lilly's EBITDA for fiscal year 2025 was $27.94 billion, a substantial increase from $15.23 billion in the previous year.
  • The company reported a net profit margin, return on equity, and operating profit margin all increased over the period.
  • Earnings per share (EPS) stood at $22.98, reflecting strong profitability.
  • Institutional investment in Eli Lilly increased by 51.8% during the fourth quarter of 2025, indicating growing confidence from investors.
  • The company is committed to scaling production of its weight-loss pill, addressing rising demand in the obesity treatment market.

Red Flags

  • Eli Lilly's market share in India's weight-loss drug sector declined from 61% to 56% in one month due to competition from generics.
  • The price-to-earnings ratio of 40.88 suggests a high valuation that may not be sustainable if growth slows.
  • The price-to-sales ratio of 13.62 and price-to-book ratio of 31.79 indicate a premium valuation relative to earnings and assets.
  • The cash conversion cycle has increased, indicating potential liquidity strain due to rising working capital.
  • Days of inventory outstanding have risen, suggesting inventory management issues.
  • Days of payables outstanding have increased, which could lead to supply chain risks if not managed properly.

Unknowns

  • The impact of rising inflation on consumer spending for healthcare products remains uncertain.
  • Eli Lilly's ability to sustain growth in the competitive weight-loss drug market is unclear amid increasing generic competition.
  • The long-term effects of the company's operational challenges on shareholder value are not fully known.

7 green flags, 6 red flags, 3 unknowns.

Overall View: Neutral/Bullish.

Action Checklist

Below are the next research steps a retail investor should consider based on this report.

Disclaimer

This Company Report is based on publicly available information and original research, and is provided for informational purposes only. It does not constitute financial, investment, or legal advice, nor an offer or solicitation to buy or sell any security. Readers should conduct their own due diligence and consult qualified advisors before making any investment decisions. Company performance can change rapidly and past results are not a guarantee of future outcomes. The author and publisher accept no responsibility for any actions taken based on this report.